References

Burden of Clostridioides difficile infection (CDI): a systematic review of the epidemiology of primary and recurrent CDI

10.1186/s12879-021-06147-y · 2021 · External reference

Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2018–2022

10.14745/ccdr.v50i06a02 · 2024 · External reference

Epidemiology of Clostridium difficile infection

10.1177/0897190013499521 · 2013 · External reference

Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults

10.1093/cid/ciab549 · 2021 · External reference

PUNCH CD3-OLS: a phase 3 prospective observational cohort study to evaluate the safety and efficacy of fecal microbiota, live-jslm (REBYOTA) in adults with recurrent Clostridioides difficile infection

10.1093/cid/ciae437 · 2025 · External reference

Short- and long-term effects of oral vancomycin on the human intestinal microbiota

10.1093/jac/dkw383 · 2017 · External reference

Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI

10.1093/cid/cis338 · 2012 · External reference

A tapered-pulsed fidaxomicin regimen following treatment in patients with multiple Clostridioides difficile infection recurrences

10.1093/cid/ciab233 · 2021 · External reference

Unresolved reference

2023 · External reference

Microbiome and metabolome restoration after administration of fecal microbiota, live-jslm (REBYOTA®) for preventing recurrent Clostridioides difficile infection

10.1093/infdis/jiae418 · 2025 · External reference

Microbiome compositional changes and clonal engraftment in a phase 3 trial of fecal microbiota, live-jslm for recurrent Clostridioides difficile infection

10.1080/19490976.2025.2520412 · 2025 · External reference

Unresolved reference

2025 · External reference

Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a Bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection

10.1007/s40265-022-01797-x · 2022 · External reference

Final results from a phase 2b randomized, placebo-controlled clinical trial of RBX2660: a microbiota-based drug for the prevention of recurrent Clostridioides difficile infection

10.1007/s40121-022-00744-3 · 2023 · External reference

Microbiota restoration reduces antibiotic-resistant bacteria gut colonization in patients with recurrent Clostridioides difficile infection from the open-label PUNCH CD study

10.1186/s13073-021-00843-9 · 2021 · External reference

Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial

10.1186/s12879-022-07256-y · 2022 · External reference

Safety of fecal microbiota, live-jslm (REBYOTA™) in individuals with recurrent Clostridioides difficile infection: data from five prospective clinical trials

10.1177/17562848231174277 · 2023 · External reference

Integrated analysis of the safety of fecal microbiota, live-jslm in adults with recurrent Clostridioides difficile infection from five prospective clinical trials: an update

10.1177/17562848251395566 · 2025 · External reference

A comparison of currently available and investigational fecal microbiota transplant products for recurrent Clostridioides difficile infection

10.3390/antibiotics13050436 · 2024 · External reference

Safety and tolerability of SER-109 as an investigational microbiome therapeutic in adults with recurrent Clostridioides difficile infection: a phase 3, open-label, single-arm trial

10.1001/jamanetworkopen.2022.55758 · 2023 · External reference

VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial

10.1001/jama.2023.4314 · 2023 · External reference

Safety and tolerability of CP101, a full-spectrum, oral microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection: a phase 2 randomized controlled trial

10.1053/j.gastro.2024.09.030 · 2025 · External reference

SER-109, an oral microbiome therapy for recurrent Clostridioides difficile infection

10.1056/nejmoa2106516 · 2022 · External reference

Faecal microbiota transplantation for recurrent C. difficile infections: challenges and improvement opportunities for clinical practice and healthcare systems

10.1111/apt.17309 · 2023 · External reference

Regional variability in fecal microbiota transplantation practices: a survey of the Southern Ontario Fecal Microbiota Transplantation Movement

10.9778/cmajo.20170109 · 2018 · External reference

Safety and efficacy of fecal microbiota, live-jslm (REBYOTA®), for the prevention of recurrent Clostridioides difficile infection in participants with inflammatory bowel disease in PUNCH CD3-OLS

10.1093/ibd/izae291 · 2025 · External reference

Safety and efficacy of fecal microbiota, live-jslm, in preventing recurrent Clostridioides difficile infection in participants who were mildly to moderately immunocompromised in the phase 3 PUNCH CD3-OLS study

10.1093/ofid/ofaf117 · 2025 · External reference